Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258933 | 0.76 | CYP19A1 (0.45) | CYP19A1CDK2CYP3A4 | |
| SCHEMBL20774868 | 0.72 | HSD17B10 (0.39) | CDK2HTR2ACYP3A4 | |
| Methoxytriphenylmethane SCHEMBL9103 | 0.70 | MAPK1 (0.48) | CYP19A1CYP3A4TSHRCES1 | |
| SCHEMBL21384637 | 0.68 | GRM5 (0.35) | CDK2GRM5CTSACSF1RNTRK1 | |
| SCHEMBL15864925 | 0.68 | CDK2 (0.54) | CDK2GRM5DRD2HTR2AHRH1 | |
| Methoxytriphenylmethane SCHEMBL27882817 | 0.68 | MAPK1 (0.46) | CYP19A1TSHRCES1 | |
| SCHEMBL2625520 | 0.67 | CDK2 (0.44) | CDK2HTR2ACYP3A4TSHRHRH4 | |
| SCHEMBL20773042 | 0.64 | CDK2 (0.41) | CDK2HTR2ACYP3A4TSHR | |
| SCHEMBL20574980 | 0.64 | CDK2 (0.41) | CYP19A1CDK2HTR2ACYP3A4TSHR | |
| SCHEMBL20773921 | 0.64 | CDK2 (0.41) | CDK2HTR2ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | CYP19A1 866/4885CDK2 2766/4885GRM5 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.